BioSpace News Archive

EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer.

Feb. 27, 2018 14:17 UTC Applied Health Analytics Launches bMetrix to Automate Biometric Data Collection, Reduce Errors at Point-of-Care Health Screening Events NASHVILLE, Tenn.--( BUSINESS WIRE )-- Applied Health Analytics, LLC has launched bMetrix™, a proprietary screening application that automates the collection of biometric data, allowing for clinicians and wellness screeners to accurately gather information at onsite and retail c

Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. Edward Hogan, M.S. as Senior Vice President of Clinical Operations. Mr. Hogan brings extensive medical imaging and clinical research experience that will significantly advance Invicro’s clinical imaging core lab capabilities across all stages of the drug development pipeline (Phase I-IV).

Role designed to build on Marek’s track record of shaping research strategy to benefit patients faster

AIVITA Biomedical, a global bio-tech wellness company specializing in novel stem cell applications, announced today its participation in three upcoming aesthetic and dermatology conferences in support of its recently launched ROOT OF SKIN™ and soon-to-launch ROOT OF SKIN™ MD skincare lines.

Median Technologies, the industry-leading Imaging Phenomics Company® (Paris:ALMDT) and CMIC HOLDINGS Co., Ltd. (CMIC), a leading Contract Research Organization (CRO) with services for development, manufacturing, sales, and marketing of pharmaceutical products, today announced a collaborative agreement for comprehensive clinical trial services.

Penumbra, Inc. reported financial results for the fourth quarter and full year ended December 31, 2017.

Bio-Rad Laboratories, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

PXL770 is observed to significantly reduce liver steatosis and NAS score following eight weeks of treatment vs control

This new mobile experience offers users the ability to track new developments related to Key Opinion Leaders, pharmaceutical products, and clinical trials in real time on their smartphones.